Mrinal S. Patnaik, M.B.B.S.

Why did you choose to study clinical and translational research?

I am a hematologist with significant interest in myeloid neoplasms, especially myelodysplastic syndromes and chronic myelomonocytic leukemia.

These disorders are uniquely enriched with epigenetic dysregulation resulting in abnormal stem cell growth, maturation and proliferation. Treatment strategies for these disorders are woefully inadequate.

To better understand these diseases and provide better treatment options for affected patients, I have decided to better train myself in the intricate nuances of clinical and translational research in the field of myeloid malignancies.

What type of research are you doing?

My research is centered on understanding epigenetic and chromatin dysregulation in patients with chronic myelomonocytic leukemia. I study transcriptional abnormalities produced in these patients secondary to mutations in epigenetic regulator genes such as TET2, ASXL1 and EZH2.

My methodologies include RNA sequencing, ChIP sequencing, and methylation and hydroxymethylation studies.

Why Mayo Clinic?

Mayo Clinic is a center of excellence for patient care, research and education. It is a prominent referral center for patients with myeloid neoplasms, especially myelodysplastic syndromes and chronic myelomonocytic leukemia.

Mayo Clinic's CCaTS is a renowned training institute. It is a unique privilege to be able to learn, practice and develop a clinical and scientific career in such a fantastic environment.

What are you looking forward to as a KL2 scholar?

I am very excited to undergo formal training in epigenetics, epigenomics, cancer and molecular biology. I hope to utilize these tools to effectively develop a career as a physician-scientist with expertise in myeloid biology.

Review Dr. Patnaik's publications on PubMed.